These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32980465)

  • 21. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G
    J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of CD4+ T cells as mediators of antitumor immunity.
    Kravtsov DS; Erbe AK; Sondel PM; Rakhmilevich AL
    Front Immunol; 2022; 13():972021. PubMed ID: 36159781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent research advances on function of CD4+T lymphocytes].
    Sun JZ; Xiao WH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):544-8. PubMed ID: 20416207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue-Resident Memory CD4
    Zhang H; Zhu Z; Modrak S; Little A
    J Immunol; 2022 Jun; 208(12):2837-2846. PubMed ID: 35589124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
    Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
    Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
    Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
    Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revisiting the role of CD4
    Tay RE; Richardson EK; Toh HC
    Cancer Gene Ther; 2021 Feb; 28(1-2):5-17. PubMed ID: 32457487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ T lymphocytes: a critical component of antitumor immunity.
    Ostrand-Rosenberg S
    Cancer Invest; 2005; 23(5):413-9. PubMed ID: 16193641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
    Kawahara M; Takaku H
    Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
    Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4
    Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
    Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resident Memory T Cells in the Tumor Microenvironment.
    Williams JB; Kupper TS
    Adv Exp Med Biol; 2020; 1273():39-68. PubMed ID: 33119875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of T helper 17 and regulatory T cells in tumor microenvironment.
    Najafi S; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):16-24. PubMed ID: 30714422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4
    Dimeloe S; Gubser P; Loeliger J; Frick C; Develioglu L; Fischer M; Marquardsen F; Bantug GR; Thommen D; Lecoultre Y; Zippelius A; Langenkamp A; Hess C
    Sci Signal; 2019 Sep; 12(599):. PubMed ID: 31530731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful.
    Kim HJ; Cantor H
    Cancer Immunol Res; 2014 Feb; 2(2):91-8. PubMed ID: 24778273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.
    Xue G; Zippelius A; Wicki A; Mandalà M; Tang F; Massi D; Hemmings BA
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26071042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.